Eris Lifesciences Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 2/6
Eris Lifesciences yıllık ortalama 4.8% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 13.3% annual. Gelirler growing yılda ortalama 17.2% oranında artmaktadır. Eris Lifesciences'in özkaynak karlılığı 11.5% ve net marjı 14%'dir.
Anahtar bilgiler
4.8%
Kazanç büyüme oranı
4.9%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 17.5% |
| Gelir büyüme oranı | 17.2% |
| Özkaynak getirisi | 11.5% |
| Net Marj | 14.0% |
| Son Kazanç Güncellemesi | 30 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly
Nov 21
Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next
Oct 30A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Oct 15Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why
Sep 19Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%
Sep 03Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Aug 05Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Aug 04Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)
Jul 13Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
May 24Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price
May 10An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued
Mar 14Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report
Feb 15Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)
Dec 28Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Nov 11Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Jul 20Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Feb 24Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?
Dec 28Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today
Sep 23If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late
May 26Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate
Apr 17Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?
Mar 12Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?
Feb 25Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar
Feb 12Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results
Jan 30
Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares
Jan 17Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay
Dec 30Gelir ve Gider Dağılımı
Eris Lifesciences nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Sep 24 | 24,853 | 3,485 | 4,773 | 0 |
| 30 Jun 24 | 22,469 | 3,803 | 4,323 | 0 |
| 31 Mar 24 | 19,913 | 3,920 | 4,217 | 0 |
| 31 Dec 23 | 18,406 | 3,864 | 3,958 | 0 |
| 30 Sep 23 | 17,750 | 3,856 | 3,841 | 0 |
| 30 Jun 23 | 17,298 | 3,824 | 3,721 | 0 |
| 31 Mar 23 | 16,618 | 3,822 | 3,548 | 0 |
| 31 Dec 22 | 15,663 | 3,970 | 3,362 | 0 |
| 30 Sep 22 | 14,766 | 3,959 | 3,104 | 0 |
| 30 Jun 22 | 13,746 | 3,940 | 2,773 | 0 |
| 31 Mar 22 | 13,262 | 4,061 | 2,622 | 0 |
| 31 Dec 21 | 12,993 | 3,941 | 2,572 | 0 |
| 30 Sep 21 | 12,763 | 3,834 | 2,553 | 0 |
| 30 Jun 21 | 12,482 | 3,728 | 2,377 | 0 |
| 31 Mar 21 | 11,926 | 3,551 | 2,439 | 0 |
| 31 Dec 20 | 11,625 | 3,432 | 2,790 | 0 |
| 30 Sep 20 | 11,192 | 3,165 | 2,717 | 0 |
| 30 Jun 20 | 10,744 | 3,015 | 2,156 | 0 |
| 31 Mar 20 | 10,582 | 2,965 | 2,317 | 0 |
| 31 Dec 19 | 10,252 | 2,943 | 2,520 | 0 |
| 30 Sep 19 | 10,119 | 3,110 | 2,470 | 0 |
| 30 Jun 19 | 9,920 | 3,036 | 1,887 | 0 |
| 31 Mar 19 | 9,672 | 2,908 | 2,453 | 0 |
| 31 Dec 18 | 9,851 | 2,925 | 2,304 | 0 |
| 30 Sep 18 | 9,442 | 2,870 | 2,258 | 0 |
| 30 Jun 18 | 9,212 | 2,945 | 1,708 | 0 |
| 31 Mar 18 | 8,196 | 2,941 | 2,027 | 0 |
| 31 Dec 17 | 8,026 | 2,800 | 1,931 | 0 |
| 30 Sep 17 | 7,781 | 2,735 | 1,818 | 0 |
| 30 Jun 17 | 7,277 | 2,505 | 1,787 | 0 |
| 31 Mar 17 | 7,205 | 2,468 | 1,737 | 0 |
| 31 Mar 16 | 5,967 | 1,112 | 1,746 | 0 |
| 31 Mar 15 | 5,456 | 892 | 1,632 | 0 |
| 31 Mar 14 | 5,088 | 704 | 1,664 | 0 |
Kaliteli Kazançlar: ERIS yüksek kaliteli kazançlar sağlıyor.
Büyüyen Kar Marjı: ERIS 'nin mevcut net kar marjları (14%) geçen yılın (21.7%) değerinden daha düşüktür.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: ERIS şirketinin kazancı son 5 yılda yılda 4.8% oranında arttı.
Büyüme Hızlandırma: ERIS 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.
Kazançlar vs. Sektör: ERIS geçtiğimiz yıl negatif kazanç büyümesine ( -9.6% ) sahipti ve bu da onu Pharmaceuticals sektör ortalamasıyla ( 20.5% ) karşılaştırmayı zorlaştırıyordu.
Özkaynak Getirisi
Yüksek ROE: ERIS 'nin Özsermaye Getirisi ( 11.5% ) düşük olarak değerlendiriliyor.